Author Archives: achicotel

About achicotel

Anthony Chicotel is a staff attorney for CANHR. His areas of expertise include the rights of long-term care residents, nursing home litigation, health care decision-making, and conservatorships.

Provider Magazine Touts Non-Pharm Dementia Care

The July 2012 issue of Provider, a magazine published by the American Health Care Association and the National Center for Assisted Living, has a cover story on finding alternatives to antipsychotics for long-term care facility residents with dementia. The article … Continue reading

Share

We are the 85%!

by Anthony Chicotel, CANHR Staff Attorney With a decent amount of fanfare, the Center for Medicare and Medicaid Services (CMS) and the nursing home trade group American Health Care Association (AHCA) recently announced an initiative to reduce the unnecessary use … Continue reading

Share

Every Resident Left Behind? OIG finds 99% of residents on antipsychotics have federally deficient care plans.

by Michael Connors, CANHR Advocate This week, the HHS Office of Inspector General (OIG) issued another stunning report on the rampant misuse of antipsychotic drugs in our nation’s nursing homes. According to the OIG, nearly every nursing home record it … Continue reading

Share

National Nursing Home Leader Says Antipsychotics Are Overprescribed

by Anthony Chicotel, CANHR Staff Attorney In a conference call with reporters, David Gifford, MD, senior vice president of quality and regulatory affairs for the American Health Care Association (AHCA) stated “we believe these antipsychotic medications are overprescribed.” He added “while … Continue reading

Share

AFL 11-08: Sea Change Without Water

by Anthony Chicotel, CANHR Staff Attorney In early 2011, DPH issued AFL 11-08 to clarify that its informed consent rules for psychotropic drugs in nursing homes applied to drugs that were prescribed prior to the resident’s admission.* The purpose of … Continue reading

Share

DPH Report: Multiple Drugging “Failures”

On May 31, the California Department of Public Health released a report summarizing the work of its Antipsychotic Collaborative and making recommendations for addressing the multiple “failures” it identified. The report recounts the myriad regulatory violations it uncovered by reviewing … Continue reading

Share

Add Depakote to Burgeoning List of Illegally Marketed Drugs

by Anthony Chicotel, CANHR Staff Attorney In what has become a disturbingly recurrent pattern, Abbott Labs has agreed to pay $1.6 billion settlement to the federal government and several states for illegally marketing a psychotropic drug as a treatment for … Continue reading

Share

CANHR’s Dementia Care Symposium Coming to So Cal on June 4 and 5!

Registration is now open for “Dementia Care Without Drugs – A Better Approach for Long-term Care Facilities” Following the phenomenal success of similar symposia in central and northern California, CANHR is co-sponsoring back-to-back full day dementia care trainings in San Diego … Continue reading

Share

Johnson and Johnson Ordered to Pay $1.2 Billion for Mis-marketing Risperdal

by Anthony Chicotel, CANHR Staff Attorney A judge recently ordered Johnson and Johnson to pay the state of Arkansas $1.2 billion for illegally marketing its antipsychotic drug Risperdal. The lawsuit included allegations that Johnson and Johnson illegally marketed Risperdal for … Continue reading

Share

The Kids Ain’t Alright

by Anthony Chicotel, CANHR Staff Attorney The National Center for Youth Law (NCYL) has announced a national project to stop the overuse of psychotropic medications on foster children.  CANHR recently met with the NCYL project leaders and we shared information … Continue reading

Share